Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on August 9, 2010, with the report dated August 20, 2010. CryoPort, Inc. entered into definitive agreements for a private placement of securities to institutional and accredited investors to raise capital for working capital purposes.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $3,202,201
- Net Proceeds: Approximately $2,945,822 (after estimated cash offering expenses)
- Securities Issued: 4,574,573 Units (each consisting of one share of Common Stock and one warrant).
- Warrant Terms: Exercise price of $0.77 per share; immediately exercisable; five-year term.
- Additional Warrants: 445,001 warrants issued to prior investors from the February 2010 public offering.
- Placement Agent Fees: 7% of aggregate gross proceeds plus expense reimbursement.
- Placement Agent Warrants: 334,500 shares to Maxim Group LLC and 305,940 shares to Emergent Financial Group, Inc. (exercise price $0.77).
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the company's operations.
Material Changes and Transaction Modifications
Following the initial agreement on August 9, 2010, the company identified that anti-dilution provisions requested by investors would trigger a default under prior debenture financings from 2007 and 2008. Consequently, on August 19, 2010, the agreements were modified to:
- Remove the problematic anti-dilution provisions.
- Grant investors a right to participate in future private placements for 24 months.
The private placement closed on approximately $3,000,000 of proceeds on August 20, 2010, with the remaining proceeds anticipated to close shortly thereafter.
Outlook, Risks, and Contingencies
- Use of Proceeds: Working capital.
- Registration Rights: The company is obligated to file a registration statement with the SEC within 60 days of the transaction close to register the resale of shares and underlying warrants.
- Penalties: The Registration Rights Agreement stipulates payments to investors if the registration statement is not filed within the required period.
- Legal Compliance: The sale was conducted under exemptions provided by Rule 505/506 of Regulation D and/or Section 4(2) of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the final closing amount of the remaining proceeds not yet closed as of August 20, 2010.
- Confirm the filing of the registration statement within the 60-day window to avoid penalty payments.
- Review the full text of the Purchase Agreements and Registration Rights Agreement in the upcoming Form 10-Q for the quarter ended September 30, 2010.
- Assess the impact of the 24-month participation right on future capital raising efforts.